2024 Annual Meeting | C192 - Multiple Sclerosis Disease-modifying Treatment

Date Thursday 04/18/24

Time 07:00 AM - 09:00 AM MDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Veronica P. Cipriani, MD

Topic(s) Multiple Sclerosis

Learning Objectives Participants should be able to identify all current options for disease-modifying treatments for multiple sclerosis; comprehend the mechanism of action of each medication, as well as the potential side effects; and judge which DMTs would be appropriate for individual patients with multiple sclerosis.

This program is supported in part by an educational grant from Novartis Pharmaceuticals.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Introductory

Program Tracks Brain Health

Recommended Audience Fellow, Resident, General Neurologist, Advanced Practice Provider

Teaching Styles Case-based, Didactic

Program Evaluations

Event Timeline
07:00 AM - 07:30 AM MDT	Speaker	Multiple Sclerosis Overview Veronica P. Cipriani, MD
07:30 AM - 08:00 AM MDT	Speaker	Mechanism of Action and Efficacy of Disease Modifying Treatments Marwa Kaisey, MD
08:00 AM - 08:30 AM MDT	Speaker	Side Effects and Monitoring Recommendations for Disease Modifying Treatments Daniel P. Kurz, MD
08:30 AM - 09:00 AM MDT	Speaker	Case Discussion Veronica P. Cipriani, MD, Marwa Kaisey, MD, Daniel P. Kurz, MD

Faculty Disclosures
Veronica P. Cipriani, MD	Dr. Penyak Cipriani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Penyak Cipriani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Penyak Cipriani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Pharmaceuticals. Dr. Penyak Cipriani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi Genzyme. Dr. Penyak Cipriani has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Penyak Cipriani has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Penyak Cipriani has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Penyak Cipriani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapeutics. Dr. Penyak Cipriani has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi. Dr. Penyak Cipriani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant with Vaccine Injury Compensation Program.
Marwa Kaisey, MD	Dr. Kaisey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG therapeutics. Dr. Kaisey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD-Serono. Dr. Kaisey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Kaisey has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Kaisey has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Genentech. Dr. Kaisey has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TG Therapeutics. Dr. Kaisey has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Venable LLC. The institution of Dr. Kaisey has received research support from NMSS. The institution of Dr. Kaisey has received research support from Race to Erase MS.
Daniel P. Kurz, MD	Dr. Kurz has nothing to disclose.

��ɫ��

��ɫ��